Effects of conbercept combined with vitrectomy on the aqueous humor VEGF and SDF-1 in patients with diabetic macular edema

doi:10.12092/j.issn.1009-2501.2019.02.016

Abstract

Abstract:

AIM: To discuss the effect of conbercept combined with vitrectomy (VT) on the aqueous humor vascular endothelial growth factor (VEGF) and human stromal cell derived factor 1 (SDF-1) in patients with diabetic macular edema (DME). METHODS: A total of 100 patients with DME were selected from March 2015 to March 2018 in our Hospital according to the random digital table method, they were divided into VT group and conbercept group, 50 cases in each group.VT group was given VT treatment while conbercept group was given extra intravitre injection therapy of conbercept. The aqueous humor VEGF, SDF-1 and complications, macular central retinal thickness (CMT), best corrected visual acuity (BCVA) were compared between the two groups. RESULTS: The postoperative aqueous humor VEGF and SDF-1 in the VT group and the conbercept group were significantly lower than those in the preoperative, the postoperative aqueous humor VEGF and SDF-1 in the VT group were significantly lower than those in the conbercept group, the difference was statistically significant (P<0.05). The complication rate in the VT group were significantly lower than those in the conbercept group, the difference was statistically significant (P<0.05). The 1 d, 1 month, 3 months postoperative BCVA and CMT in the VT group and the conbercept group were significantly lower than those in the preoperative, the 1 d, 1 month, 3 months postoperative BCVA and CMT in the VT group were significantly lower than those in the conbercept group, the difference was statistically significant (P<0.05). CONCLUSION: Conbercept combined with VT can effectively improve the aqueous humor VEGF and SDF-1 in patients with DME, which is beneficial to reduce the complications, and it can effectively improve BCVA and CMT in patients, it's worth for further clinical promotion.

Key words: conbercept, vitrectomy, diabetic macular edema, vascular endothelial growth factor, human stromal cell derived factor 1

CLC Number:

R774.5

ZHANG Huang, QUAN Chanjuan, YANG Xinhuai, HUANG Shulan, GAO Songzhe, WANG Xiao, CHEN Rong, CHEN Lan. Effects of conbercept combined with vitrectomy on the aqueous humor VEGF and SDF-1 in patients with diabetic macular edema[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 218-222.

References

［1］Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies［J］. Ophthalmol, 2015,122(10): 2044-2052.
［2］Korobelnik JF,Schmidt Do DV,Erf ur th U,et al.Intrav itreal aflibereept for diabetic macular edema［J］.Ophthalmol,2014,121(11):2247-2254.
［3］牛红霞,吉昂.玻璃体腔注射康柏西普联合视网膜光凝治疗糖尿病性黄斑水肿的疗效观察［J］.解放军医学杂志,2018,43(3):268-270.
［4］高静,刘晓,王敏哲,等.VEGF、SDF-1在糖尿病视网膜血管病变发生、发展中的作用及机制［J］.新疆医科大学学报,2016,39(10):1286-1290.
［5］李凤鸣.中华眼科学［M］.第2版.北京:人民卫生出版社,2005:2165-2171.
［6］温积权,曹永葆,汪怿,等.羟苯磺酸钙联合血栓通对糖尿病视网膜病变致患者视野缺损的临床疗效［J］.中国临床药理学杂志,2016,32(1):12-14.
［7］Tripathy K, Sharma YR, Singh HI, et al.Scleral abscess fol-lowing posterior subtenon triamcinolone acetonide injection fordiabetic macular edema［J］. Saudi J Ophthalmol, 2016,30(2):130-132.
［8］于文洲,杨颖.中药联合玻璃体切割术治疗难治性黄斑水肿的疗效分析［J］.中医临床研究,2017,9(9):51-53.
［9］Shimura M,Yasuda K,Minezaki T,et al.Reduction in the fre-quency of intravitreal bevacizumab administrations achieved byposterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema［J］.Jpn J Ophthalmol,2016,60(5):401-407.
［10］戴琰琰,史春生,王勇,等.观察康柏西普联合激光光凝治疗糖尿病性黄斑水肿临床疗效［J］.实用防盲技术,2018,13(1):3-6.
［11］Moon J,Kim M, Sagong M.Combination therapy of intravit-real bevacizumab with single simultaneous posterior subtenontriamcinolone acetonide for macular edema due to branch retinal vein occlusion［J］. Eye (Lond) ,2016,30(8) : 1084-1090.
［12］王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性［J］.眼科新进展,2016,36(5):471-473.
［13］Xu Y, Rong A, Xu W, et al.Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study［J］.BMC Ophthalmol, 2017,17(1):158.
［14］王智勇,刘丽萍,高永峰.糖尿病视网膜病变患者血清Gas6、SDF-1α和SDF-1β变化及意义［J］.国际眼科杂志,2017,17(5):861-864.
［15］Cavalla F, Osorio C, Paredes R, et al. Matrix metalloproteinases regulate extracellular levels of SDF-1/CXCL12, IL-6 and VEGF in hydrogen peroxide- stimulated human periodontal ligament fibroblasts［J］. Cytokine 2015,73 ( 1 ) : 114-121.
［16］蒋莉,李劲,聂爱芹.玻璃体腔注射康柏西普治疗糖尿病黄斑水肿的疗效观察［J］.国际眼科杂志,2017,17(6):1105-1107.
［17］林再雄,李科.玻璃体切割术联合曲安奈德治疗糖尿病性黄斑水肿的黄斑区变化［J］.实用药物与临床,2017,20(3):300-303.
［18］Miller CG, Budoff G,Jeng-Miller KW, et al.Retina specialists treating diabetic macular edema recommend different approaches for patients than they would choose for themselves［J］. Ophthalmic Surg Lasers Imaging Retina, 2016,47(6):544-554.

[1]	LU Ruibin, ZHAO Hui, XIE Qiuling, HU Lu, GUO Chaowan, PEI Yunlin, XIONG Sheng. Anti-FGF-2 nanobody inhibits rat corneal angiogenesis induced by alkali burn [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 609-615.
[2]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[3]	JING Qindong, LIU Haipeng, WANG Binru, CHEN Kang, CHEN Xiao. Progress of apatinib in the treatment of advanced gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1194-1200.
[4]	LI Xiaojie,ZHANG Shengwei,WANG Huasheng,WANG Dong, MEI Jiazhuan, DENG Yewei. Effects of polymorphism of vascular endothelial growth factor A on the prognosis of colorectal cancer patients received fluorouracil based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 900-904.
[5]	XIA Lijuan, HE Yunqin, SHAO Mingjun. Efficacy of levonorgestrel intrauterine system in the treatment of dysfunctional uterine bleeding [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 699-704.
[6]	XU Buyuan, PAN Xiange, CHEN Chongbie, CAI Min, XU Lu. Effects of curcumin on VEGF and endostatin expression of Lewis lung carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 151-154.
[7]	LIN Guo-Fang. Effects of Curcumin on VEGF and AQP - 4 of rats with focal cerebral ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(6): 621-624.
[8]	XU Xiao-fang, ZHANG Lei-lei, JIA Ren-bing, ZHOU Yi-xiong, SONG Xin, FAN Xian-qun. Expression and clinical significant of matrix metalloproteinase-2 in sebaceous carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 557-561.
[9]	JIANG Ai-ying, YU Ren-zhi, LV Yu-feng, LUO Hai-long. Therapeutic effect of VEGF receptor inhibitor SU5614 in a murine model of toluene diisocyanate induced asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 269-273.
[10]	WU Chun-yan, WANG Wei, CHEN Xin, CHEN Dong-yun, RUI Jing. Efficacy and therapeutic mechanism of recombinant human endostatin on malignant ascites in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 507-511.
[11]	MIAO Hua-chun, WU Feng, DING Jian, XIONG Ke-ren. Effects of polysaccharide of gastrodia elata blume and electroacupuncture on the expressions of brain derived neurotrophic factor and vascular endothelial growth factor in dentate gyrus of cerebral ischemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 260-264.
[12]	WANG Sheng-ye, DU Xiang-hui. Benefit-risk Evaluation of Bevacizumab in the treatment of Breast Cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 115-120.
[13]	YE Yi-lu, ZHANG Qi, ZHANG Jian-ting, ZHANG Xiao-hua, YU Yue-ping, WEI Er-qing. Protective effects of cilostazol on the chronic ischemic brain injury in mice and its action mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 130-134.
[14]	SUN Jing. Effect of Yiqiyangyin Fang on vascular endothelial growth factor expression in tumor cells transplanted on chick chorioallantoic membrane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 265-268.
[15]	GAO Xue-Qin, HAN Jin-Xiang, ZHANG Wei-Dong, SONG Shou-Qin, ZHU Bo. Effects of aspirin and sulindac on expression of cyclooxygenase-2, vascular endothelial growth factor, laminin receptor, and CD₄₄V₆ in 3AO cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 906-910.